Robert van der Vaart, MD
Ophthalmology · Wilmington, NCNPI 1538450499
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 73.6% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $11,629, more than ten times the $752 reported in 2019. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $217.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Glaukos Corporation$8K
- Alcon$1K
- Ivantis, Inc$538
- Biotissue Holdings Inc.$501
- Johnson & Johnson Surgical Vision, Inc.$420
- plus $2K from 15 others
Across 2 payments — averaging $1400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$3K
What the payments were for
- Consulting fees$15,67532%
- Speaking & faculty fees$22,67546%
- Travel & lodging$4,1348%
- Food & beverage$6,92514%
- Education$1130%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $36,459 |
| Glaukos Corporation | 17 | $8,495 |
| Alcon | 36 | $1,482 |
| Ivantis, Inc | 16 | $538 |
| Biotissue Holdings Inc. | 27 | $501 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $420 |
| Sun Pharmaceutical Industries Inc. | 12 | $259 |
| NEW World Medical,inc. | 4 | $250 |
| Rxsight Inc | 2 | $233 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $142 |
| Amgen | 1 | $124 |
| Carl Zeiss Meditec, Inc. | 1 | $121 |
| Rayner Intraocular Lenses Limited | 6 | $109 |
| Sight Sciences, Inc. | 3 | $92 |
| Dompe US, Inc. | 3 | $88 |
| Kala Pharmaceuticals, Inc. | 5 | $81 |
| Bausch & Lomb Americas Inc. | 4 | $72 |
| Novartis | 2 | $38 |
| Harrow Eye, LLC | 1 | $29 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$30,080
- RESTASIS$4,976
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,500
- Travoprost Intraocular Implant - iDose$1,300
- Hydrus Microstent$236
- iStent inject W$153
- IACCESS$153
- Centurion$145
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$141
- Kahook Dual Blade$140
- Clearpath$140
- Ahmed Glaucoma Valve$140
- Streamline$140
- Via360$140
- AcrySof IQ PanOptix UV IOL$132
- AcrySof IQ VIVITY$132
- Hydrus$125
- TEPEZZA$124
- AcrySof IQ PanOptix$122
- CIRRUS HD-OCT$121
How this compares
$49,567 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 123 | $46,890 |
| RestasisCyclosporine | 41 | $38,679 |
| RocklatanNetarsudil Mesylat/Latanoprost | 76 | $30,600 |
| VyzultaLatanoprostene Bunod | 72 | $24,682 |
| CombiganBrimonidine Tartrate/Timolol | 98 | $23,831 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 107 | $19,279 |
| RhopressaNetarsudil Mesylate | 52 | $17,311 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 53 | $15,829 |
| Prednisolone Acetate | 438 | $13,356 |
| Travoprost | 63 | $10,422 |
| MoxifloxacinMoxifloxacin Hcl | 286 | $8,303 |
| Latanoprost | 907 | $7,712 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 437 | $6,756 |
| Lotemax SmLoteprednol Etabonate | 25 | $6,177 |
| Ketorolac Tromethamine | 214 | $5,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $36,459 | $114,014275 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $72 | $24,68272 claims |
| AlconSimbrinza | $1,482 | $15,82953 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $142 | $6,17725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Wilmington
- Matej PolomskyWilmington$20K
- Samantha WatsonWilmington$11K
- Clark SpringsWilmington$10K
- Alan BrownWilmington$10K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.